These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23330907)

  • 1. Emerging drugs for managing kidney disease in patients with diabetes.
    Thomas MC
    Expert Opin Emerg Drugs; 2013 Mar; 18(1):55-70. PubMed ID: 23330907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New approaches to the treatment of nephropathy in diabetes.
    Thomas MC; Groop PH
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1057-71. PubMed ID: 21745151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving glycemic control in patients with type 2 diabetes and renal impairment.
    Avogaro A; Schernthaner G
    Acta Diabetol; 2013 Jun; 50(3):283-91. PubMed ID: 23212669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs for chronic kidney disease.
    Stefoni S; Cianciolo G; Baraldi O; Iorio M; Angelini ML
    Expert Opin Emerg Drugs; 2014 Jun; 19(2):183-99. PubMed ID: 24836744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.
    Fang V; Wazny LD; Raymond CB
    CANNT J; 2012; 22(1):30-6; quiz 37-8. PubMed ID: 22558681
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of diabetes-related chronic kidney disease.
    Reddy N
    Nephrol News Issues; 2011 Jun; 25(7):20, 22. PubMed ID: 21736131
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease.
    Swaminathan S; Shah SV
    Curr Opin Nephrol Hypertens; 2008 Mar; 17(2):143-8. PubMed ID: 18277146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drugs for diabetic nephropathy.
    Bruno S; Cattaneo D; Perico N; Remuzzi G
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):747-71. PubMed ID: 16262561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin and endothelin antagonists in chronic kidney disease.
    Kohan DE; Barton M
    Kidney Int; 2014 Nov; 86(5):896-904. PubMed ID: 24805108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel avenues for treating diabetic nephropathy: new investigational drugs.
    Lacava V; Pellicanò V; Ferrajolo C; Cernaro V; Visconti L; Conti G; Buemi M; Santoro D
    Expert Opin Investig Drugs; 2017 Apr; 26(4):445-462. PubMed ID: 28277032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting inflammation in diabetic nephropathy: a tale of hope.
    Moreno JA; Gomez-Guerrero C; Mas S; Sanz AB; Lorenzo O; Ruiz-Ortega M; Opazo L; Mezzano S; Egido J
    Expert Opin Investig Drugs; 2018 Nov; 27(11):917-930. PubMed ID: 30334635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endothelin system and endothelin receptor antagonists.
    Jandeleit-Dahm KA; Watson AM
    Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):66-71. PubMed ID: 22123210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chronic kidney disease and new antidiabetic drugs : an overview in 2019].
    Andrade Lopes S; Jornayvaz FR; De Seigneux S
    Rev Med Suisse; 2019 May; 15(653):1106-1111. PubMed ID: 31148421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on potential drugs for the treatment of diabetic kidney disease.
    Shepler B; Nash C; Smith C; Dimarco A; Petty J; Szewciw S
    Clin Ther; 2012 Jun; 34(6):1237-46. PubMed ID: 22578309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rational hypoglycemic therapy - nephro-diabetologic view].
    Kosmalski M; Kurnatowska I
    Pol Merkur Lekarski; 2018 Aug; 45(266):81-88. PubMed ID: 30240375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease.
    Fraune C; Lange S; Krebs C; Hölzel A; Baucke J; Divac N; Schwedhelm E; Streichert T; Velden J; Garrelds IM; Danser AH; Frenay AR; van Goor H; Jankowski V; Stahl R; Nguyen G; Wenzel UO
    Am J Physiol Renal Physiol; 2012 Oct; 303(7):F1037-48. PubMed ID: 22791343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antidiabetic agents and renal insufficiency].
    Robles NR; Blanco J
    Nefrologia; 2002; 22(4):325-8. PubMed ID: 12369123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.